The Effect of Inhaled Salbutamol on Residual Capacity in Patients with Chronic Obstructive Pulmonary Disease

Document Type: Original article


1 Department of Pulmonology, School of Medicine, Iran University of Medical Sciences, Tehran, Iran

2 Department of Pulmonology, School of Medicine, Zahedan University of Medical Sciences, Tehran, Iran


Background: It is now hypothesized that anti-asthmatic agents such as bronchodilators can reduce residual capacity and Residual Volume (RV) along with inducing no change in Total Lung Capacity (TLC). In the present study, an attempt was made to assess RV following administration of salbutamol inhaled in patients with Chronic Obstructive Pulmonary Disease (COPD).
Methods: This prospective interventional case series was conducted on 119 patients with COPD who referred to Rasoul-e-Akram Hospital in Tehran, Iran in 2015. At the beginning of the study, the patients were assessed using spirometer and plethysmograph (BodyBox) and RV was measured. Then, inhaled 400 µg salbutamol (Four puffs) was administered and the RV, TLC and the ratio of RV to TLC (RV/TLC) was measured again 15 min later.
Results: Regarding the change in parameters of lung volumes after salbutamol administration, although Forced Expiratory Volume in one second (FEV1) and FEV1/FVC (Forced Vital Capacity-FVC) ratio is significantly increased, the deduction of RV and TLC would be much more. RV decreased from 217.02±123.72% before intervention to 167.50±30.91% after that (p<0.001). There was also no difference between men and women in the change of RV (142.99±52.30% vs. 37.78±36.99%, p=0.37). Compared to smokers, nonsmokers had experienced more reduction in RV (142.50±60.06% vs. 57.79±11.20% p=0.01). The change in RV was adversely associated with age. There was no relation between COPD severity and the change in RV and also RV to TLC.
Conclusion: The use of salbutamol inhaled in COPD patients even 15 min after administration leads to significant decrease in RV and RV to TLC ratio even more than increment in FEV1 and FEV1/FVC ratio.


1. Aliverti A, Stevenson N, Dellacà RL, Lo Mauro A, Pedotti A, Calverley PM. Regional chest wall volumes during exercise in chronic obstructive pulmonary disease. Thorax 2004;59(3):210-6.

2. National Collaborating Centre for Chronic Conditions. Chronic obstructive pulmonary disease. National clinical guideline on management of chronic obstructive pulmonary disease in adults in primary and secondary care. Thorax 2004;59(Suppl I):1-232.

3. Jones PW. Health status measurement in chronic obstructive pulmonary disease. Thorax 2001;56(11):880-7.

4. Sutherland ER, Cherniack RM. Management of chronic obstructive pulmonary disease (review). N Engl J Med 2004;350(26):2689-97.

5. Hay JG, Stone P, Carter J, Church S, Eyre-Brook A, Pearson MG, et al. Bronchodilator reversibility, exercise performance and breathlessness in stable chronic obstructive pulmonary disease. Eur Respir J 1992;5(6):659-64.

6. O’Donnell DE, Flüge T, Gerken F, Hamilton A, Webb K, Aguilaniu B, et al. Effects of tiotropium on lung hyperinflation, dyspnoea and exercise tolerance in COPD. Eur Respir J 2004;23(6):832-40.

7. O’Donnell DE, Lam M, Webb KA. Spirometric correlates of improvement in exercise performance after anticholinergic therapy in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1999;160(2):542-9.

8. Berger R, Smith D. Acute postbronchodilator changes in pulmonary function parameters in patients with chronic airways obstruction. Chest 1988;93:541-5.

9. Richter DC, Joubert JR, Nell H, Schuurmans MM, Irusen EM. Diagnostic value of post-bronchodilator pulmonary function testing to distinguish between stable, moderate to severe COPD and asthma. Int J Chron Obstruct Pulmon Dis 2008;3(4):693-9.

10. Holmes PW, Campbell AH, Barter CE. Acute changes of lung volumes and lung mechanics in asthma and normal subjects. Thorax 1978;33(3):394-400.

11. Ramirez-Venegas A, Ward J, Lentine T, Mahler DA. Salmeterol reduces dyspnea and improves lung function in patients with COPD. Chest 1997;112(2)336-40.

12. Hankinson JL, Odencrantz JR, Fedan KB. Spirometric reference values from a sample of the general US population. Am J Respir Crit Care Med 1999;159(1):179-87.    

13. Tantucci C, Duguet A, Similowski T, Zelter M, Derenne JP, Milic-Emili J. Effect of salbutamol on dynamic hyperinflation in chronic obstructive pulmonary disease patients. Eur Respir J 1998 Oct;12(4):799-804.

14. Newton MF, O’Donnell DE, Forkert L. Response of lung volumes to inhaled salbutamol in a large population of patients with severe hyperinflation. Chest 2002 Apr;121(4):1042-50.

15. Aliverti A, Rodger K, Dellacà RL, Stevenson N, Mauro AL, Pedotti A, et al. Effect of salbutamol on lung function and chest wall volumes at rest and during exercise in COPD. Thorax 2005;60(11):916-24.

16. Balestra AM, Bingisser RB. Bronchodilator response in residual volume in irreversible airway obstruction. Swiss Medical Weekly 2008;138(17-18):251-5.

17. Dellaca RL, Pompilio PP, Walker PP, Duffy N, Pedotti A, Calverley PM. Effect of bronchodilation on expiratory flow limitation and resting lung mechanics in COPD. Eur Respir J 2009;33(6):1329-37.

18. McCartney CT, Weis MN, Ruppel GL, Nayak RP. Residual volume and total lung capacity to assess reversibility in obstructive lung disease. Respir Care 2016;61(11):1505-12.